Hydrogenology
Source-linked study record

Hydrogen-rich saline ameliorated LPS-induced acute lung injury via autophagy inhibition through the ROS/AMPK/mTOR pathway in mice

Wang Y, Zhang J, Bo J, Wang X, Zhu J. · Experimental Biology and Medicine. 2019;244(9):721-727.

PreclinicalOther formsPublished 2019Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Preclinical

Population or model

Forty male C57BL/6 mice in an intratracheal lipopolysaccharide acute-lung-injury model, with MLE-12 cell experiments.

Intervention and dose

H₂-rich saline 10 mL/kg intraperitoneally one hour before intratracheal LPS; cell culture medium was replaced with H₂-rich medium one hour before LPS. · H₂ was dissolved for six hours at 0.4 MPa, prepared within 24 hours and measured at an average 0.86 mmol/L.

Duration

Pretreatment one hour before LPS; mice were killed 12 hours later, while cell endpoints used article-specific intervals up to 24 hours.

Reported result

H₂-rich saline/medium was associated with improved injury and oxidative/inflammatory measures and lower autophagy/AMPK activation. Total AMPK and total mTOR protein did not change significantly. The study tested pretreatment, not rescue after established acute lung injury.

Main limitation

Small short-term preclinical prevention model, nonclinical surrogate endpoints, unclear exact per-group mouse allocation, and pathway inference based partly on pharmacologic inhibitors in cells. Authors reported no financial support and declared no conflicts.

Evidence and classification

What kind of evidence is this?

Evidence type

Preclinical

Reported design

Randomized five-group mouse experiment plus controlled mouse lung-cell assays

Research topic

Respiratory health

Administration form

Other forms

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

Forty male C57BL/6 mice in an intratracheal lipopolysaccharide acute-lung-injury model, with MLE-12 cell experiments.

Sample

40 mice randomized among control, saline, LPS, H₂-rich saline plus LPS, and 3-methyladenine plus LPS groups. The text does not explicitly state equal per-group allocation; cell assays report three independent experiments.

Duration

Pretreatment one hour before LPS; mice were killed 12 hours later, while cell endpoints used article-specific intervals up to 24 hours.

Intervention

H₂-rich saline 10 mL/kg intraperitoneally one hour before intratracheal LPS; cell culture medium was replaced with H₂-rich medium one hour before LPS.

Hydrogen form

H₂ dissolved in saline or cell-culture medium — H₂ only, not Brown's gas.

Dose or H₂ specification

H₂ was dissolved for six hours at 0.4 MPa, prepared within 24 hours and measured at an average 0.86 mmol/L.

Comparator

Control/saline, LPS injury and autophagy-inhibitor 3-methyladenine groups; mechanistic cell comparisons also used NAC and compound C.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Lung histology, wet/dry ratio, MDA, bronchoalveolar protein and inflammatory cells, cell viability/ROS, autophagy markers and AMPK/mTOR signaling.

Reported result

H₂-rich saline/medium was associated with improved injury and oxidative/inflammatory measures and lower autophagy/AMPK activation. Total AMPK and total mTOR protein did not change significantly. The study tested pretreatment, not rescue after established acute lung injury.

Extraction completeness

The complete free PMC article was checked for animal groups, H₂ preparation/concentration, dose and timing, in-vivo and cell results, a reported null molecular result, funding and conflict declaration.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Small short-term preclinical prevention model, nonclinical surrogate endpoints, unclear exact per-group mouse allocation, and pathway inference based partly on pharmacologic inhibitors in cells. Authors reported no financial support and declared no conflicts.

Applies directly to

Acute LPS lung injury in mice/cells; it does not establish treatment of human ARDS or sepsis.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 31042074 · DOI: 10.1177/1535370219847941

Publisher access

Free full article in PubMed Central.

Extraction basis

Complete PMC article and PubMed metadata; full-text extraction checked 9 August 2026.

Last reviewed

10 August 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.